Neurogene
NGNE
27.49
+1.62
+6.26%
Neurogene
US · NGNE
#3726 by market cap
27.49
+1.62
+6.26%
Live - 5344 symbols - heartbeat 465s ago
· 2026-10-08 10:11
Pre-market
28.04
+8.39%
After-hours
25.87
0.00%
Overnight
26.11
+0.93%
- Market cap
- 550.11M
- P/E (TTM)i
- -5.45
- P/Bi
- 2.53
- EPSi
- -4.24
- Div yieldi
- 0.00%
- 52W posi
- 42%
Reader sentiment
Are you bullish or bearish on NGNE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 24.3 percentage points.
Institutional ownership
- Held by institutions
- 88.91% -24.31pp
- Institutions
- 143 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund38.77%
Mutual Fund24.64%
VC/PE Fund18.11%
Individual/Insider7.01%
Public Company4.91%
Sovereign Wealth Fund1.84%
Private Company0.44%
Insurance Company0.12%
Other4.09%
Top holders as of 2026-06-30
Samsara BioCapital LLC
8.58% · 1.72M sh
Casdin Capital, LLC
7.72% · 1.55M sh
Redmile Group, LLC
7.06% · 1.41M sh
RTW Investments, LP
6.81% · 1.36M sh
Rachel McMinn
6.64% · 1.33M sh
EcoR1 Capital, LLC
6.35% · 1.27M sh
BlackRock
5.29% · 1.06M sh
Baker Bros. Advisors LP
4.96% · 991.69K sh
Balyasny Asset Management L.P.
4.09% · 818.71K sh
Trails Edge Capital Partners, LP
3.57% · 714.89K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 37 buys · 11 sells
| Name | Role | Stake |
|---|---|---|
| Rachel McMinn | Chief Executive Officer | 6.64% |
| Christine Cvijic | President, CFO & Secretary | 0.19% |
| Cory Freedland | Director | 0.17% |
| Julie Jordan | Chief Medical Officer | 0.01% |
| Robert Baffi | Director | -- |
| Rohan Palekar | Director | -- |
| Sarah Noonberg | Director | -- |
| Samsara Biocapital, L.P. | -- | -- |
| Samsara BioCapital LLC | -- | -- |
| Robert Woods | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-21 | Rachel McMinn | Chief Executive Officer | Derivative Exercise and Retained | +756 | $25.32 |
| 2026-07-06 | Christine Cvijic | President, CFO & Secretary | Automatic Disposition | -4,800 | $36.02–36.13 |
| 2026-07-01 | Christine Cvijic | President, CFO & Secretary | Automatic Disposition | -4,800 | $34.06–35.23 |
| 2026-05-05 | Christine Cvijic | President, CFO & Secretary | Automatic Disposition | -9,600 | $30.07–32.44 |
| 2026-05-04 | Christina Shafer | Chief Commercial Officer | Other Derivative Acquisition | +120,000 | $28.94 |
| 2026-03-25 | Rachel McMinn | Chief Executive Officer | Open Market Disposition | -3,352 | $22.07 |
| 2026-03-25 | Christine Cvijic | President, CFO & Secretary | Open Market Disposition | -2,558 | $21.62 |
| 2026-03-25 | Julie Jordan | Chief Medical Officer | Open Market Disposition | -828 | $21.89 |
| 2026-03-12 | Christine Cvijic | President, CFO & Secretary | Open Market Disposition | -4,045 | $20.42–22.02 |
| 2026-03-12 | Stuart Cobb | Chief Scientific Officer | Automatic Disposition | -6,797 | $20.41–22.08 |
| 2026-02-26 | Christine Cvijic | President, CFO & Secretary | Automatic Disposition | -4,800 | $25.11 |
| 2026-02-19 | Robert Baffi | Director | Other Derivative Acquisition | +12,050 | $17.64 |
| 2026-02-19 | Rohan Palekar | Director | Other Derivative Acquisition | +12,050 | $17.64 |
| 2026-02-19 | Rachel McMinn | Chief Executive Officer | Other Acquisition | +25,900 | -- |
| 2026-02-19 | Rachel McMinn | Chief Executive Officer | Other Derivative Acquisition | +155,100 | $17.64 |
| 2026-02-19 | Sarah Noonberg | Director | Other Derivative Acquisition | +12,050 | $17.64 |
| 2026-02-19 | Christine Cvijic | President, CFO & Secretary | Other Acquisition | +22,000 | -- |
| 2026-02-19 | Christine Cvijic | President, CFO & Secretary | Other Derivative Acquisition | +131,900 | $17.64 |
| 2026-02-19 | Cory Freedland | Director | Other Derivative Acquisition | +12,050 | $17.64 |
| 2026-02-19 | Robert Woods | Independent Director | Other Derivative Acquisition | +12,050 | $17.64 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:11:03 · For reference only, not investment advice and not tailored to your situation.